NTSR1 and cancer: While 48 benign samples out of 66 were positively labeled with an NTR1 antibody, with weak staining in most of them, NTR1 was significantly overexpressed in cancer samples compared to nonmalignant tissues with global staining nearly 14-fold higher in endometrial adenocarcinomas using immunohistochemistry.